Skip to Main Content
Contribute Try STAT+ Today

In an unusual bid to address prescription drug costs, Pfizer (PFE) is promising to offer warranties for its Xalkori lung cancer treatment and will refund the entire cost to any patient and health plan if the medication fails to work within the first three months.

The drug maker last June quietly began what it calls a pilot program, which runs through the end of this year, for anyone who is covered by Medicare or commercial insurance, or pays by cash. Called the Pfizer Pledge, the program has escaped notice because the company has, so far, not publicized the effort beyond describing the details on its web site.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment